Health Care [ 8/12 ] | Biotechnology [ 36/76 ]
NASDAQ | Common Stock
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas.
Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials.
It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors.
The company was founded in 2017 and is headquartered in Bethesda, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.42 Increased by +32.26% | -0.20 Decreased by -110.00% |
| May 14, 24 | -0.22 Increased by +48.84% | -0.29 Increased by +24.14% |
| Mar 26, 24 | -0.36 Increased by +7.69% | -0.32 Decreased by -12.50% |
| Nov 14, 23 | -0.37 Increased by +2.63% | -0.45 Increased by +17.78% |
| Aug 10, 23 | -0.62 Decreased by -44.19% | -0.31 Decreased by -100.00% |
| May 12, 23 | -0.43 Decreased by -53.57% | -0.39 Decreased by -10.26% |
| Mar 23, 23 | -0.39 Decreased by -21.88% | -0.38 Decreased by -2.63% |
| Nov 10, 22 | -0.38 Increased by +2.56% | -0.46 Increased by +17.39% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -8.14 M Decreased by -5.92% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -4.01 M Increased by +21.86% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 64.80 K Decreased by -53.75% | -4.72 M Decreased by -1.06% | Decreased by -7.29 K% Decreased by -118.51% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -4.72 M Decreased by -3.51% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -7.69 M Decreased by -51.18% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 55.18 K Increased by +22.61% | -5.14 M Decreased by -56.98% | Decreased by -9.31 K% Decreased by -28.03% |
| Dec 31, 22 | 140.11 K Increased by +285.54% | -4.67 M Decreased by -45.17% | Decreased by -3.34 K% Increased by +62.35% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -4.56 M Increased by +2.26% | Decreased by N/A% Decreased by N/A% |